BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins, and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Corgenix manufactures the BG Medicine Galectin-3 ELISA product, an in-vitro diagnostic product used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.